Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

21. [Optimal long-term use of proton pump inhibitors]

[Optimal long-term use of proton pump inhibitors] Usage optimal à long terme des inhibiteurs de la pompe à protons [Optimal long-term use of proton pump inhibitors] Usage optimal à long terme des inhibiteurs de la pompe à protons [Optimal long-term use of proton pump inhibitors] Tremblay E, Tardif M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Tremblay E, Tardif M. Usage optimal à long terme des inhibiteurs de la pompe à protons. [Optimal long-term use of proton pump inhibitors] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). 2016 Authors' conclusions Upon gathering information from good clinical practice recommendations and during multiple consultations, INESSS made the following observations: • Prescribing PPIs is unwarranted in many cases. • It will take more than clinical tools and training

Health Technology Assessment (HTA) Database.2017

22. Proton Pump Inhibitors and Kidney Disease—GI Upset for the Nephrologist?

Proton Pump Inhibitors and Kidney Disease—GI Upset for the Nephrologist? 28845467 2018 11 13 2468-0249 2 3 2017 May Kidney international reports Kidney Int Rep Proton Pump Inhibitors and Kidney Disease - GI Upset for the Nephrologist? 297-301 10.1016/j.ekir.2017.01.005 Widely regarded as safe and effective, proton pump inhibitors (PPIs) are among the most commonly used medications in the world today. However, a spate of observational studies suggest an association between PPI use and adverse (...) events, including infection, bone fracture, and dementia. This review details evidence linking the use of PPI therapy to the development of kidney disease, including early case reports of acute interstitial nephritis and subsequent large observational studies of acute kidney injury (AKI), chronic kidney disease (CKD), and end-stage renal disease (ESRD). The majority of studies showed higher risk of kidney outcomes among persons prescribed PPI medications, with effect sizes that were slightly higher

Kidney international reports2017 Full Text: Link to full Text with Trip Pro

23. Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable?

Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,500 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca (...) June 26, 2017 Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable? Clinical Question: How successful are attempts to stop PPIs and how can clinicians improve chances of success? Bottom Line: Using a range of deprescribing strategies, about 25% of patients with gastroesophageal reflux disease (GERD) or dyspepsia can stop PPI use and another 30-50% can decrease their dose. Older patients and those who taper appear more successful in stopping PPIs. Evidence: • Clustered randomized

Tools for Practice2017

24. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study.

Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. Objective To examine the risk of community acquired pneumonia before and after prescription of proton pump inhibitor (PPI) and assess whether unmeasured confounding explains this association. Design Cohort study and self controlled case series. Setting Clinical Practice Research Datalink (1990 to 2013) in UK. Participants Adult patients with a new prescription for a PPI (...) individually matched with controls. Main outcome measures Association of community acquired pneumonia with PPI prescription estimated by three methods: a multivariable Cox model comparing risk in PPI exposed patients with controls, corrected for potential confounders; a self controlled case series; and a prior event rate ratio (PERR) analysis over the 12 month periods before and after the first PPI prescription. Results 160 000 new PPI users were examined. The adjusted Cox regression showed a risk

BMJ2016 Full Text: Link to full Text with Trip Pro

25. A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease

A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease | Therapeutics Initiative Independent Healthcare Evidence > > A systematic review of the comparative effectiveness of proton pump inhibitors (...) for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease This was produced by the Drug Assessment Working Group of the Therapeutics Initiative at the request of the Pharmaceutical Services Division (PSD) of the British Columbia Ministry of Health as part of the Drug Effectiveness Review Project (DERP), a class review of proton pump inhibitors (PPIs) for the treatment of adult patients with symptomatic GERD or PUD. Research questions Four research questions were

Therapeutics Letter2016

26. Comparative effectiveness of proton pump inhibitors

Comparative effectiveness of proton pump inhibitors March - April 2016 99 © Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Comparative effectiveness of proton pump inhibitors Comparative trials of PPIs in adult patients with symptomatic PUD Based on 6 RCTs in 1753 patients, esomeprazole was not significantly different from other PPIs for most outcome (...) patients, lansoprazole was not significantly different from other PPIs for most outcome measures: H. pylori eradication; mortality; serious adverse events; withdrawal due to adverse events; and patients with at least one adverse event. Total sympto- matic relief, time to first resolution of symptoms, recurrence or relapse of symptoms and quality of life scores were not reported. 7 Overall Risk of Bias assessment RCTs remain our best source evidence, but unfor- tunately can be biased. 8 Selection bias

Therapeutics Letter2016

27. Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors

Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors 27419077 2016 07 15 2018 11 13 2214-5400 9 2016 Sep Meta gene Meta Gene Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors. 159-64 10.1016/j.mgene.2016.06.004 Polymorphisms in genes encoding drug metabolizing enzymes may lead to varied enzyme activity and inter-individual variability in drug (...) efficacy and/or toxicity. Since CYP2C19 and CYP3A4 genes code for enzymes involved in metabolizing wide variety of drugs including proton pump inhibitors, we sought to identify polymorphisms in these genes in order to study their impact on drug metabolism in subjects. DNA was isolated from healthy individuals including tribals and genotyped for 11 single nucleotide polymorphisms in CYP2C19 and 6 polymorphisms in CYP3A4. Individuals were categorized into different phenotypes based on their drug

Meta gene2016 Full Text: Link to full Text with Trip Pro

28. Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors

Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors 27398293 2018 11 13 2199-1154 3 2 2016 Jun Drugs - real world outcomes Drugs Real World Outcomes Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors. 145-154 Subacute cutaneous lupus erythematosus (SCLE) is an autoimmune disease that may be induced by proton pump inhibitors (PPIs) in at-risk populations. The US FDA does not recognize SCLE as an adverse event (...) associated with PPIs. We queried the FDA Adverse Event Reporting System database, which contains adverse event case reports submitted by the public as well as by industry, and analyzed the data to quantify passive pharmacovigilance signals for SCLE associated with PPIs. A disproportionality analysis of the signals yielded a significant association between SCLE and PPIs. Discontinuation of PPI resulted in remission, with PPI re-challenge causing SCLE to reoccur. A follow-up analysis also yielded

Drugs - real world outcomes2016 Full Text: Link to full Text with Trip Pro

29. Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines

Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department (...) Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Published on: February 5, 2016 Project Number: RC0740-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

30. Concern for Myocardial Infarction Risk Associated with Proton Pump Inhibitor Use in Patients With No Underlying Cardiovascular Disease

Concern for Myocardial Infarction Risk Associated with Proton Pump Inhibitor Use in Patients With No Underlying Cardiovascular Disease "Concern for Myocardial Infarction Risk Associated with Proton Pump Inh" by Natasha K. Ludwig < > > > > > Title Author Date of Award Fall 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Saje Davis-Risen, PA-C, MS Second Advisor Annjanette Sommers, PA-C, MS Rights . Abstract Background (...) : Proton pump inhibitors (PPIs) are the drugs of choice when it comes to the treatment of dyspepsia and gastroesophageal reflux disease (GERD). Recently, the FDA issued a warning regarding concomitant use of omeprazole, a PPI, with clopidogrel as it interferes with CYP2C19 activity. The pharmacological activity of clopidogrel is decreased, possibly increasing the potential for an acute cardiac event. However, there is limited evidence with regards to myocardial infarct (MI) risk with use of PPIs alone. The purpose

Pacific University EBM Capstone Project2016

31. Are We Overusing Proton Pump Inhibitors?

Are We Overusing Proton Pump Inhibitors? Are We Overusing Proton Pump Inhibitors? | Clinical Correlations Are We Overusing Proton Pump Inhibitors? November 13, 2015 By Shimwoo Lee Peer Reviewed Case: A 31-year-old man with poorly controlled type 2 diabetes was hospitalized for community-acquired pneumonia. His home medications included esomeprazole. When asked why he was receiving this medication, the patient said it was first started during his prior hospitalization for “ulcer prevention (...) ” eight months ago and that he had continued to take it since. He denied any history of upper gastrointestinal symptoms. Esomeprazole was tapered off during this admission. When being discharged after successful treatment of his pneumonia, he was told he no longer needed to take esomeprazole. Proton pump inhibitors (PPIs) are one of the most widely used medications in the US. Last year, esomeprazole was ranked as one of the top three [1]. PPIs are the most potent inhibitors of gastric secretion

Clinical Correlations2015

32. [Notice of the impact of the decrease of the maximum payable amount for the class of proton pump inhibitors]

[Notice of the impact of the decrease of the maximum payable amount for the class of proton pump inhibitors] Avis sur l'impact de la baisse du prix maximal payable sur la classe des inhibiteurs de la pompe à protons [Notice of the impact of the decrease of the maximum payable amount for the class of proton pump inhibitors] Avis sur l'impact de la baisse du prix maximal payable sur la classe des inhibiteurs de la pompe à protons [Notice of the impact of the decrease of the maximum payable amount (...) for the class of proton pump inhibitors] Jehanno C, Robitaille J, Bouchard S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Jehanno C, Robitaille J, Bouchard S. Avis sur l'impact de la baisse du prix maximal payable sur la classe des inhibiteurs de la pompe à protons. [Notice of the impact of the decrease of the maximum payable amount for the class

Health Technology Assessment (HTA) Database.2015

33. Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus

Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus - GOV.UK GOV.UK uses cookies to make the site simpler. Search Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus From: Published: 8 September 2015 Therapeutic area: and Proton pump inhibitors (PPIs) are associated with very infrequent cases of subacute cutaneous lupus erythematosus (SCLE), a non-scarring (...) dermatosis that can develop in sun-exposed areas. Contents If a patient treated with a proton pump inhibitor ( Proton pump inhibitors A review of medical records of patients at a dermatology unit in a university hospital in Denmark identified 19 cases of A further 17 cases of Cumulatively, of the cases reviewed from literature and from case reports submitted by Sandholdt LH and others. Proton pump inhibitor-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2014; 170: 342–51. Almebayadh M

MHRA Drug Safety Update2015

34. Proton Pump Inhibitors for Gastrointestinal Conditions

Proton Pump Inhibitors for Gastrointestinal Conditions Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along (...) . It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Proton Pump Inhibitors for Gastrointestinal Conditions: A Review

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

36. Proton Pump Inhibitors in Upper GI Bleeds

Proton Pump Inhibitors in Upper GI Bleeds Emergency Medicine > Journal Club > Archive > August 2015 Toggle navigation August 2015 Proton Pump Inhibitors in Upper GI Bleeds Vignette You're working a shift in EM-­‐2 one day when you pick up a patient with the chief\ complaint of "bloody emesis." The patient is a 45 year old male with a history of chronic low back pain who takes daily naproxen (250 mg BID). His pain worsened two months ago when he was in an MVC, and he has been taking ibuprofen (...) PT/INR and PTT are normal. An NG tube is placed and returns coffee grounds with streaks of blood that do not clear after lavage with one liter of normal saline. You order a type and screen and cross him for 4 units (just incase). You call the GI fellow, thinking that the patient probably needs an upper endoscopy. The GI fellow asks that you start the patient on a continuous infusion of intravenous antoprazole. You wonder how useful IV proton pump inhibitors actually are in the setting of upper GI

Washington University Emergency Medicine Journal Club2015

37. Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up

Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up Suivi de la mesure de remboursement des inhibiteurs de la pompe à protons (IPP) [Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up] Suivi de la mesure de remboursement des inhibiteurs de la pompe à protons (IPP) [Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up] Régie de l'assurance maladie du Québec, Jehanno C, Baril J, Chamberland C Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Régie de l'assurance maladie du Québec, Jehanno C, Baril J, Chamberland C. Suivi de la mesure de remboursement des inhibiteurs de la pompe à protons (IPP). [Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). 2014 Authors

Health Technology Assessment (HTA) Database.2014

38. Proton Pump Inhibitors Versus Histamine 2 Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients: A Systematic Review and Meta-Analysis

Proton Pump Inhibitors Versus Histamine 2 Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients: A Systematic Review and Meta-Analysis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2014

39. Proton Pump Inhibitors: Acid Suppression with a Nutritional Cost

Proton Pump Inhibitors: Acid Suppression with a Nutritional Cost Proton Pump Inhibitors: Acid Suppression with a Nutritional Cost | Clinical Correlations Proton Pump Inhibitors: Acid Suppression with a Nutritional Cost June 13, 2014 By Dana Zalkin Peer Reviewed In the late 1970s evidence began to emerge that a newly discovered pump, [1]. With this discovery, further research [2]. We now have drugs that do just that: the proton pump inhibitors (PPIs). Proton pump inhibitors have been used since (...) 1989 to treat acid-related gastrointestinal [3, 4]. In 2011, the PPI omeprazole was the sixth most commonly dispensed prescription medication in the [5]. Given the chronicity of many acid-related disorders, such as gastroesophageal reflux disease (GERD), many patients ultimately end up taking PPIs daily for many years. With this in mind, it is important to consider the potential side effects of PPIs and assess the costs and benefits of long-term PPI use. One potential side effect of PPIs is the

Clinical Correlations2014

40. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis

Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis Alhazzani W, Alenezi F (...) , Jaeschke RZ, Moayyedi P, Cook DJ CRD summary The review concluded that, in critically ill patients, proton pump inhibitors seemed more effective than histamine 2 receptor antagonists in preventing clinically important and overt upper gastrointestinal bleeding, but limitations in the evidence mean that these findings should not be considered as being robust. The authors' conclusions are likely to be reliable. Authors' objectives To determine the efficacy and safety of proton pump inhibitors compared

DARE.2014